ScinoPharm Taiwan, Ltd. (1789) and Nano Targeting & Therapy (NTT) initiated an agreement for a licensing mode technology transfer in December 2022 to establish a collaborative development plan based on a technology that utilizes mesoporous silica nanoparticle (MSN) to deliver docetaxel to treat brain cancer. This nanoparticle drug delivery platform has numerous innovative advantages. Compared with liposomes, the main benefit is adjustability, which includes the surface area, pore volume, pore structure, and particle size. MSNs also exhibit superior chemical stability. Surface modification of MSNs can optimize selectivity and specificity to enhance drug efficacy.

ScinoPharm continues to develop diverse collaborations with partners to seize opportunities. ScinoPharm has the most significant number of highly reactive anticancer drugs and peptide products. Combining them with NTT's nanoparticle drug delivery technology will create new opportunities to solve challenges posed by traditional drugs and technologies. Moreover, this collaboration symbolizes ScinoPharm's entry into drug delivery, as well as a good opportunity for promoting the new drug, 505(b)2, and a step towards a new milestone in multi-strategy development.